These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The serum bactericidal activity of domestic fleroxacin and lomefloxacin].
    Author: Zhao M, Jiang S, Wang R.
    Journal: Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):98-100. PubMed ID: 11798634.
    Abstract:
    OBJECTIVE: To evaluate antibacterial activities in vivo and in vitro of fleroxacin and lomefloxacin. METHODS: Minimal inhibitory concentration (MIC) and serum bactericidal activity (SBA) domestic fleroxacin and lomefloxacin were determined by agar disk dilution method and microplate method respectively. A clinical observation of fleroxacin and lomefloxacin for treating acute bacillary dysentery was carried out. RESULTS: MIC(90) of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae, S. aureus was 0.25-2 mg/L, being the same as that of ofloxacin. However, MIC(90) of lomefloxacin against the above mentioned species was twice or fourfold as that of ofloxacin and fleroxacin. The percent age of peak SBA > or = 1:8 with ofloxacin, fleroxacin and lomefloxacin against E. coli, K. pneumoniae, S. dysenteriae was 80%-100%, 90%-100% and 50%-80% respectively (P < 0.01). The clinical cure rates of acute bacillary dysentery were 93.3%, 100% and 100% and the bacterial clearance rates were 93.3%, 100% and 100% in the lomefloxacin, fleroxacin and ofloxacin group respectively. CONCLUSION: The antibacterial activity in vivo and in vitro of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae was similar to that of ofloxacin and stronger than that of lomefloxacin.
    [Abstract] [Full Text] [Related] [New Search]